Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Vaccinex (VCNX) has issued an update.
Vaccinex, Inc. has announced the completion of the final patient visit in its SIGNAL-AD Phase 1b/2 study, evaluating pepinemab as a treatment for Alzheimer’s disease. This milestone marks a significant step forward in the development of the drug, capturing the interest of investors and stakeholders in the potential impact on Alzheimer’s treatment and Vaccinex’s future prospects.
For a thorough assessment of VCNX stock, go to TipRanks’ Stock Analysis page.
